| Followers | 5 |
| Posts | 259 |
| Boards Moderated | 0 |
| Alias Born | 07/03/2025 |
Tuesday, March 03, 2026 1:37:13 PM
Activist investors don’t reveal their strategy. They gaslight people to gain control which is what they did here. Retail is always misinformed. Try and tell me differently. LMAO.
This is not seismic. It’s basic patent lifecycle management looking at codified regulations and knowing the path forward using the codified regulations , science and how medicine is practiced.
Remember when you and others criticized and critiqued along this bumpy path? It’s as bad as the Amarin can’t do share buy backs theory peddled here and other free apps that talk stocks.
Prior management talked about the FDC because it was low hanging fruit. They were retards and deviants. They had other plans for this. It was snatched from them before it was too late and now it’s in the hands of a guy that has done worse damage with value but at least has a plan.
Of course it would be the same as in EU. This will be rolled out globally but in someone else’s hands.Amarin, as constituted is a collection of failures. This is now about selling the idea of Amarin/Vascepa and what can be done with it moving forward. Good luck putting a valuation on that. The DCF modeling based on the current situation is FUBAR. Remember, you said Grok was high. The USA market is viable and that infringement case is now a smoke screen. Infringement can be dispatched with a new patent and an authorized generic. We lost that battle long ago and 10 generics exist and they are not going away. Any money we can make from an authorized generic is gravy competing in the SHTG space. We have a CVD IFU and can probably get a second IFU based on the science and whatever path the FDA chooses for them but I’d rather that be in the hands of BP that can walk all over regulators at FDA. If it’s in someone else’s hands it’s all doable. This is why Barclays is here. This is also why share buybacks aren’t done. That pile of cash in someone else’s hands is valuable. So are the carry forwards.
This is not seismic. It’s basic patent lifecycle management looking at codified regulations and knowing the path forward using the codified regulations , science and how medicine is practiced.
Remember when you and others criticized and critiqued along this bumpy path? It’s as bad as the Amarin can’t do share buy backs theory peddled here and other free apps that talk stocks.
Prior management talked about the FDC because it was low hanging fruit. They were retards and deviants. They had other plans for this. It was snatched from them before it was too late and now it’s in the hands of a guy that has done worse damage with value but at least has a plan.
Of course it would be the same as in EU. This will be rolled out globally but in someone else’s hands.Amarin, as constituted is a collection of failures. This is now about selling the idea of Amarin/Vascepa and what can be done with it moving forward. Good luck putting a valuation on that. The DCF modeling based on the current situation is FUBAR. Remember, you said Grok was high. The USA market is viable and that infringement case is now a smoke screen. Infringement can be dispatched with a new patent and an authorized generic. We lost that battle long ago and 10 generics exist and they are not going away. Any money we can make from an authorized generic is gravy competing in the SHTG space. We have a CVD IFU and can probably get a second IFU based on the science and whatever path the FDA chooses for them but I’d rather that be in the hands of BP that can walk all over regulators at FDA. If it’s in someone else’s hands it’s all doable. This is why Barclays is here. This is also why share buybacks aren’t done. That pile of cash in someone else’s hands is valuable. So are the carry forwards.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
